[The antitumor activity of L-asparaginase].
D000818:Animals; D000970:Antineoplastic Agents; D001215:Asparaginase / Q000009:adverse effects / Q000097:blood / Q000138:chemical synthesis / Q000302:isolation & purification / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use* / Q000633:toxicity / Q000652:urine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007668:Kidney / Q000032:analysis; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality; D007942:Leukemia, Experimental / Q000188:drug therapy; D007953:Leukemia, Radiation-Induced / Q000188:drug therapy; D008099:Liver / Q000032:analysis; D008115:Liver Regeneration / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D012190:Retroviridae / Q000187:drug effects; D013154:Spleen / Q000032:analysis; D013950:Thymus Gland / Q000032:analysis
D000970:Antineoplastic Agents; D001215:Asparaginase
Le proprietà antitumorali della L-asparaginasi.